DEveloping BBB-ASL as non-Invasive Early biomarker of Alzheimer’s Disease (DEBBIE-AD): Study design

Padrela, Beatriz E.; Mahroo, Amnah; Tee, Mervin; Sneve, Markus H.; Moyaert, Paulien; Geier, Oliver; Kuijer, Joost P. A.; Beun, Soetkin; Nordhøy, Wibeke; Zhu, Yufei David; Buck, Mareike A.; Hoinkiss, Daniel C.; Konstandin, Simon; Huber, Jörn; Wiersinga, Julia; Rikken, Roos; de Leeuw, Diederick; Grydeland, Håkon; Tippett, Lynette; Cawston, Erin E.; Ozturk-Isik, Esin; Linn, Jennifer; Brandt, Moritz; Tijms, Betty; van de Giessen, Elsmarieke; Muller, Majon; Fjell, Anders M.; Walhovd, Kristine B.; Pålhaugen, Lene; Selnes, Per; Clement, Patricia; Achten, Eric; Anazodo, Udunna; Barkhof, Frederik; Hilal, Saima; Fladby, Tormod; Eickel, Klaus; Morgan, Catherine; Thomas, David L.; Petr, Jan; Günther, Matthias; Mutsaerts, Henk J. M. M.

DEveloping BBB-ASL as non-Invasive Early biomarker of Alzheimer’s Disease (DEBBIE-AD): Study design

Padrela, B. E.; Mahroo, A.; Tee, M.; Sneve, M. H.; Moyaert, P.; Geier, O.; Kuijer, J. P. A.; Beun, S.; Nordhøy, W.; Zhu, Y. D.; Buck, M. A.; Hoinkiss, D. C.; Konstandin, S.; Huber, J.; Wiersinga, J.; Rikken, R.; de Leeuw, D.; Grydeland, H.; Tippett, L.; Cawston, E. E.; Ozturk-Isik, E.; Linn, J.; Brandt, M.; Tijms, B.; van de Giessen, E.; Muller, M.; Fjell, A. M.; Walhovd, K. B.; Pålhaugen, L.; Selnes, P.; Clement, P.; Achten, E.; Anazodo, U.; Barkhof, F.; Hilal, S.; Fladby, T.; Eickel, K.; Morgan, C.; Thomas, D. L.; Petr, J.; Günther, M.; Mutsaerts, H. J. M. M.

Abstract

Introduction: Loss of blood-brain barrier (BBB) integrity is hypothesized to be one of the earliest microvascular signs of Alzheimer’s disease (AD). Arterial spin labeling (ASL) perfusion MRI has recently been adapted to map the BBB permeability non-invasively. This article outlines the study design of the DEveloping BBB-ASL as a non-Invasive Early biomarker (DEBBIE) consortium, focused on investigating the potential of BBB-ASL as an early biomarker for AD (DEBBIE-AD).
Methods: DEBBIE-AD consists of 13 cohorts enrolling participants from subjective cognitive decline to AD, as well as healthy controls across the lifespan. The reproducibility and accuracy of BBB-ASL will be evaluated in healthy participants, and its clinical value will be evaluated with both established and novel AD biomarkers.
Expected endpoints: DEBBIE-AD aims to provide evidence on the ability of BBB-ASL to measure BBB permeability and demonstrate its utility in AD-related pathologies, which may provide new targets for treatment.

Beteiligte Forschungsanlagen

PET-Zentrum

Poster
VasCog 2023 - The 14th International Conference of The International Society of Vascular Behavioural and Congnitive Disorders, 13.09.2023, Goteborg, Sweden

Permalink: https://www.hzdr.de/publications/Publ-37560